This content is not available in your region

Roche sales better than forecast

Roche sales better than forecast
Text size Aa Aa

Swiss drugmaker Roche’s sales in the first-three months of the year were better than expected – up by six percent on the same period last year at 8.5 billion euros.

It credits a pick up demand for key cancer drugs after destocking by wholesalers at the end of last year as well as increased demand for its flu drug Tamiflu.

The world’s largest maker of cancer drugs also confirmed its full-year sales forecast.